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Abstract 
Esophageal adenocarcinoma is rapidly increasing in incidence in many Western societies, 
requires demanding treatment and is associated with a poor prognosis, therefore 
preventive measures are highly warranted. To assess the opportunities for prevention, we 
reviewed the available literature and identified seven main potentially preventive targets. 
Preventive effects were found based on medium level observational evidence following 
treatment of gastroesophageal reflux disease (both using medication and surgery) and 
tobacco smoking cessation, which should be clinically recommended among exposed 
patients. Non-steroidal anti-inflammatory drugs appears to prevent esophageal 
adenocarcinoma, and the limited existing data also indicates a protective effect of 
medication with statins or hormone replacement therapy in women, but current evidence is 
insufficient to guide clinical decision-making regarding these drugs. The evidence is 
presently insufficient to assess the potentially preventive role of weight loss. Whether 
avoidance of eradication of Helicobacter pylori prevents esophageal adenocarcinoma is not 
studied, but there is no evidence that such eradication increases symptoms of gastro-
esophageal reflux or prevalence of erosive esophagitis. The introduction of preventive 
actions should be tailored towards high-risk individuals, i.e. older men with obesity and 
gastroesophageal reflux disease and individuals with Barrett’s esophagus rather than the 
population at large. 
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Introduction 
Esophageal cancer is the eighth most common cancer and the sixth most deadly cancer 
worldwide (1). There are two major histological types of esophageal cancer, 
adenocarcinoma and squamous cell carcinoma; squamous cell carcinoma is most common 
worldwide, while esophageal adenocarcinoma (EAC) is more common in the Western world, 
especially among white men (1-3). While the incidence of squamous cell carcinoma is 
decreasing, EAC is characterized by a rapidly increasing incidence among white populations 
in high-income countries.(3) The increase seems to have begun in the early 1970’s, and in 
the United States the annual incidence increased from 0.40 cases per 100 000 individuals in 
1975, to 2.58 per 100 000 in 2009 (4, 5). Changes in prevalence of the main etiological 
factors, i.e. gastroesophageal reflux, obesity and infection with Helicobacter pylori (H. 
pylori), have most likely contributed to the increase (2). Potentially curatively intended 
treatment of EAC requires demanding and extensive surgery, often followed by severe 
postoperative complications, including mortality, and severe deterioration in health-related 
quality of life (2). Despite recent advances in detection and treatment of EAC, the overall 
prognosis remains poor, with a 5-year overall survival of approximately 15%. The 5-year 
survival following curatively intended treatment varies greatly (range 24-55%) in Western 
societies, a variation that at least partly depends on differences in selection of patients for 
surgery (6-8). The rapidly increasing incidence, demanding treatment and poor prognosis 
highlight the need for preventive measures, especially among high-risk individuals. Such 
high-risk groups might be those with a combination of risk factors of EAC or those with the 
premalignant condition Barrett’s esophagus, a specialized columnar metaplasia replacing 
the native squamous epithelium of the distal esophagus in response to chronic 
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gastroesophageal reflux (9). We conducted a review assessing potential targets for 
preventing EAC. 
 
Search criteria 
The literature search to identify relevant studies assessing factors that might prevent EAC 
was conducted using PubMed, Web of Science, and the Cochrane library. The search strings 
were combinations of different exposures and EAC, with the primary aim of identifying 
relevant systematic reviews meta-analyses, and secondarily original studies. Due to the rare 
incidence of EAC, studies including high-grade dysplasia were also included, although there 
is a risk of inter-observer variation regarding high-grade dysplasia (10, 11). We only included 
studies of human subjects, and excluded case reports and publications in other languages 
than English. Backward and forward citation tracking was conducted to further identify 
relevant literature. The best level of evidence  regarding each of these factors was rated 
according to the Oxford Centre for Evidence-based Medicine’s level of evidence, where the 
level of evidence is graded as: 1 (randomized controlled trials), 2 (cohort studies), 3 (case-
control studies), 4 (case-series), and 5 (expert opinions); grades 1-3 are further denoted as 
a) systematic review, or b) individual study (12). Furthermore, the recommendations were 
assessed according to the Oxford Centre for Evidence-based Medicine’s grades of 
recommendations, graded as: A (consistent level 1 studies), B (consistent level 2 or 3 studies 
or extrapolations from level 1 studies), C (level 4 studies or extrapolations from level 2 or 3 
studies), D (level 5 evidence of troublingly inconsistent or inconclusive studies of any level 
(12).  
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Seven potentially preventive measures 
The literature search identified seven factors of particular relevance for prevention: 1) 
treatment of gastroesophageal reflux, 2) weight loss among obese individuals, 3) tobacco 
smoking cessation, 4) avoidance of eradication of H. pylori-infection, 5) hormone 
replacement therapy, 6) use of nonsteroidal anti-inflammatory drugs, and 7) use of statins. 
The results of the literature search and evidence grade regarding each of the seven factors 
are summarized in Table 1. We indicate population-based studies for studies employing this 
sampling frame, whereas the rest were non-population based.  
 
Treatment of gastroesophageal reflux  
Gastroesophageal reflux disease (GERD) is a common condition with a reported prevalence 
ranging from 10 to 20% in most Western societies. GERD is also the main risk factor for EAC, 
an association established in the late 1990’s (13, 14). A recent meta-analysis (including five 
population-based case-control studies) found that the odds ratio (OR) of EAC was nearly 5 
times higher among individuals experiencing weekly reflux symptoms (heartburn or acid 
regurgitation) than those with less frequent or no such symptoms (OR 4.92, 95% confidence 
interval [CI] 3.90-6.22), and over 7-fold increased for individuals experiencing daily reflux 
symptoms (OR 7.40, 95% CI 4.94-11.1) (15). GERD can be treated medically, typically using 
proton-pump inhibitors (PPI), or surgically, with fundoplication. PPIs are generally 
considered to be the first line of treatment, while surgery is mainly an option if inadequate 
response is achieved from adequate doses of PPI or when treatment is believed to be 
ongoing for a long time, particularly in younger individuals (16). Studies have shown that 
long-term use of PPI increases the serum levels of gastrin, which in turn is believed to 
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promote cell-survival in the gastrointestinal tract and might facilitate carcinogenesis from 
Barrett’s esophagus, and it is debated whether this in a long-term clinical setting could 
increase the risk of EAC (17-19). Most earlier studies have failed to show reduction in risk of 
EAC following PPI use, but rather indicated an increased risk. However, these results are 
debated since they might be due to confounding by the severity of GERD, i.e., those with 
severe GERD, who have the highest risk of EAC, are more likely to be prescribed PPIs than 
those with mild reflux. A recent meta-analysis (including four hospital-based cohort studies, 
one population-based cohort study and two case-control studies) concluded that there was 
a decreased risk of EAC or high-grade dysplasia among patients with Barrett’s esophagus 
who used PPIs compared to non-users (OR 0.29, 95% CI 0.12-0.79) (20). On the other hand, 
a recent Danish population-based case-control study assessing the risk of EAC following PPI 
treatment found an increased risk of high-grade dysplasia or EAC following treatment with 
PPIs, with a relative risk of 2.2 (95% CI 0.7-6.7) and 3.4 (95% CI 1.1-10.5) among long-term 
low- and high-adherence users, respectively (21). However, also, after combining this Danish 
study with the results from the previous meta-analysis (20), a protective effect of PPIs on 
EAC remained (22).  
Fundoplication is generally performed laparoscopically, where the fundus of the stomach is 
wrapped completely or partially around the lower part of the esophagus. Since individuals 
eligible for fundoplication tend to have particularly severe GERD or GERD that did not 
respond satisfactorily to PPIs, a valid comparison with untreated patients is usually not 
feasible. Yet, a recent meta-analysis (including 10 cohort studies, of which 2 were 
population-based, and 2 RCTs) comparing patients undergoing fundoplication with medically 
treated patients indicated a non-significantly decreased pooled incidence rate ratio (IRR) of 
EAC in favor of surgery (IRR 0.76, 95% CI 0.42-1.39), and the risk estimate further decreased 
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but remained nonsignificant in analyses restricted to patients with Barrett’s esophagus (IRR 
0.46, 95% CI 0.20-1.08) (23). In an analysis restricted to studies published after the year 
2000, when the surgically treated patients typically underwent laparoscopic fundoplication, 
the IRR was statistically significantly decreased in patients with Barrett’s esophagus (IRR 
0.26, 95% CI 0.09-0.79) (23).  
Taken together, there is medium level evidence that medical treatment of GERD have a 
preventive effect on the development of EAC, although it is debated whether long-term use 
of PPI might actually have a carcinogenic effect on Barrett’s esophagus (evidence level 3a, 
grade of recommendation D). There is also medium level evidence suggesting that 
prevention of EAC following surgical treatment of GERD goes in line with, or might be 
slightly more effective, than medical treatment (evidence level 2a, grade of 
recommendation B).  
 
Weight loss 
There is a strong association between high body mass index (BMI) and many cancer types, 
but a comprehensive meta-analysis (based on 221 datasets) concluded that EAC had the 
strongest association with BMI (24). A recent meta-analysis (22 studies; 14 case-control 
studies, of which 12 were population-based, and 8 population-based cohort studies) found 
that compared to individuals with normal BMI, the overall risk ratio (RR) of EAC was 1.71 
(95% CI 1.50-1.96) for individuals with a BMI 25-30, and 2.34 for those with a BMI ≥30 (95% 
CI 1.95-2.81) (25). A pooled analysis of 12 observational studies (10 population-based case-
control studies and 2 population-based cohort studies) comparing individuals with a BMI 
<25 with those with a BMI ≥40, found an OR of EAC of 3.65 (95% CI 2.50-5.34) (26). The 
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available literature indicates a linear association between increasing BMI and risk of EAC. A 
meta-analysis (2 population-based cohort studies, 1 hospital-based cohort study and 3 
population-based case-control studies) concluded that abdominal or visceral adiposity, 
independent of BMI, significantly increased the risk of EAC (27). The increased risk of 
esophageal metaplasia and EAC due to obesity is attributable to mechanical effects of 
obesity (e.g. gastroesophageal reflux), but also metabolic and endocrine effects (such as 
macrophage activation and release of proinflammatory cytokines) (28). 
Despite the established association between BMI and EAC, the potentially preventive role of 
weight loss is uncertain. This is at least partly due to inherent problems in assessing weight 
loss as an exposure in larger cohorts, and challenges in identifying a large enough cohort of 
individuals with voluntary weight loss that is both substantial and long-lasting. In this 
context, obesity surgery might be seen as a potential human model for assessing the risk of 
developing EAC following weight loss, because of its drastic and stable long-term weight 
reduction starting from a specific date (29, 30). However, a recent systematic review 
identified only 11 cases of EAC occurring after obesity surgery, and statistical analyses were 
not conducted (31). In a subsequent population-based cohort study in Sweden, including 
34,437 patients undergoing obesity surgery, only 8 participants developed EAC during 
follow-up, resulting in a hazard ratio of 0.9 (95% CI 0.4-1.9) compared to non-operated 
obese individuals (32). This might be explained by the rather short follow-up time in the 
studies published to date, where there might be a longer period of time before a risk 
reduction can be seen, or attributable to metabolic or endocrine effects due to obesity. 
Thus, no clearly preventive effect of obesity surgery was revealed, although the statistical 
power was low.  
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In summary, while obesity is associated with increased EAC risk, there is only limited 
evidence indicating that weight loss does not decrease the risk of EAC among obese 
individuals. However, long follow-up of large cohorts of patients, e.g. those undergoing 
obesity surgery, should provide important knowledge regarding this topic (evidence level 
2b, grade of recommendation B). 
 
Tobacco smoking cessation 
Tobacco smoking is associated with a moderately increased risk of EAC. A meta-analysis 
based on 33 studies (30 case-control studies, of which 13 were population-based, and 3 
cohort studies, of which 2 were population-based) found a RR of 1.76 (95% CI 1.54-2.01) for 
EAC, including the gastric cardia, when comparing ever and never smokers (33). A pooled 
analysis of 10 population-based case-control studies found an OR of 2.08 (95% CI 1.83-2.37) 
when comparing ever and never smokers (34). The pooled analysis found that smoking 
cessation decreased the risk of EAC, and that a longer time since smoking cessation reduced 
the risk increase in a time-dependent manner (34). Compared to current smokers, smoking 
cessation <10 years entailed an OR of 0.82 (95% CI 0.60-1.13), and smoking cessation of ≥10 
years entailed an OR of 0.71 (95% CI 0.56-0.89) (34). However, the risk of EAC among 
previous smokers did not return to the level of non-smokers; even after ≥10 years of 
smoking cessation, the pooled analysis, found a 1.7-fold risk of EAC compared to never 
smokers (34). There are currently no published cohort studies regarding smoking cessation. 
Thus, there is consistent evidence showing that tobacco smoking cessation decreases the 
risk of EAC among tobacco smokers, although the risk might not return to the level of never 
smokers (evidence level 3b, grade of recommendation B). 
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Avoiding eradication of Helicobacter pylori  
H. pylori is a gram-negative bacterium, and has been determined to be a main risk factor for 
peptic ulceration and gastric adenocarcinoma (35-37). A systematic review including 37 
studies from 22 countries found that the infection is generally acquired during childhood 
and the prevalence is over 50% in many populations (38). Infection with H. pylori can lead to 
atrophy of the gastric mucosa, resulting in lower volume and acidity of gastric juices, which 
in turn could decrease the risk of EAC (39). In keeping with this hypothesis, a meta-analysis 
of 20 studies (11 case-control studies and 9 cohort studies) found a 40% lower prevalence of 
H. pylori among patients with GERD compared to patients without GERD (OR 0.60, 95% CI 
0.47-0.78) (40), and two recent meta-analyses (including 9 cohort studies and 9 case-control 
studies of which 3 were population-based, and including 15 case-control studies, of which 8 
were population-based) found that ongoing infection with H. pylori was associated with a 
nearly halved risk of EAC (OR 0.52, 95% CI 0.37-0.73, and 0.59, 95% CI 0.51-0.68) (41, 42). 
These findings indicate that broad eradication strategies might not be justified in high-risk 
individuals of EAC. However, no studies have assessed the association between H. pylori-
eradication and EAC. Nevertheless, a recent meta-analysis (including 7 randomized clinical 
trials and 5 cohort studies) found no significant association between eradication of H. pylori-
infection and prevalence of symptomatic GERD or endoscopically documented GERD (43). 
Another meta-analysis (including 16 cohort studies), although with some overlap with the 
previously cited meta-analysis, found no association between H. pylori-eradication and 
symptomatic GERD or erosive esophagitis when analyzing the studies based on sub-groups 
for geographic region, age, baseline disease or length of follow-up (44).  
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Taken together, the limited literature has no direct evidence to determine if eradication of 
H. pylori increases the risk of EAC, i.e. if avoidance of eradication might be justified in some 
individuals. However, such eradication does not seem to increase the risk of GERD or 
erosive esophagitis, and since these are risk factors of developing EAC, this might indicate 
that there is no increased risk for EAC per se (evidence level 2a, grade of recommendation 
D).  
 
Hormone replacement therapy 
A possible explanation for the strong male predominance of EAC, with an average three to 
six fold higher incidence among men (45), is differences in levels of endogenous exposure to 
female sex hormones. If this hypothesis is true, preventive effects of exogenous HRT might 
be evident. HRT is administered mainly for climacteric symptoms in postmenopausal 
women, and has been shown to be effective for treating vasomotor symptoms, vaginal 
atrophy, and sexual problems, as well as in preventing osteoporosis and bone fractures (46-
49). A meta-analysis including five studies (2 population-based cohort studies, 2 case-control 
studies and 1 pooled analysis of four case-control studies) found a decreased odds ratio of 
EAC among ever users of HRT, compared to never users (OR 0.75, 95% CI 0.58-0.98), 
however, no sub analyses based on dosage, type or duration was possible due to few and 
small studies (50). A recent case-control study found an increased risk of GERD symptoms 
(HR 1.57, 95% CI 1.45-1.70) when comparing ever users of HRT with never users, but no 
increased risk of Barrett’s esophagus (HR 1.15, 95% CI 0.81-1.63) or EAC (HR 0.89, 95% CI 
0.28-2.82) was found (51). 
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Thus, the available literature addressing HRT in relation to risk of EAC to date is limited, but 
might suggest a preventive effect (evidence level 3a, grade of recommendation B).  
 
Non-steroidal anti-inflammatory drugs 
NSAIDs inhibit cyclooxygenase (COX) on a systemic level, either unselected or COX-2 
specifically, and are usually administered for their analgesic, anti-inflammatory, and 
antipyretic effects (52, 53). COX-2 is an inflammatory enzyme necessary for the production 
of prostaglandins and other inflammatory mediators, and there is an increased expression 
of COX-2 in patients with Barrett’s esophagus and EAC, hence indicating the possibility of 
chemoprevention if targeting this mechanism (54-56). A pooled analysis of six studies (5 
population-based case-control studies and 1 population-based cohort study) found a 
reduced risk of EAC among ever-users of any NSAID, including aspirin, compared to never-
users (OR 0.68, 95% CI 0.56–0.82) (57). Compared to never-users, a slightly stronger 
reduction was indicated among daily users of any NSAIDS, including aspirin (OR 0.56, 95% CI 
0.43-0.73), than occasional users (OR 0.66, 95% CI 0.44-1.00) (57). A meta-analysis (including 
eight randomized clinical trials) found that daily treatment with aspirin was followed by a 
reduction in 20-year risk of death due to esophageal adenocarcinoma (HR 0.36, 95% CI 0.21-
0.63) (58). Another meta-analysis (including 9 case-control studies, of which 4 were 
population-based, and 1 population-based cohort study) assessing NSAID use and risk of 
EAC found an OR of 0.64 (95% CI 0.52-0.79) among users of  aspirin and 0.65 (0.50-0.85) 
among users of non-aspirin NSAIDs, compared to never-users (59).  
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In summary, treatment with NSAIDs appears to decrease the risk of developing EAC 
(evidence level 1a, grade of recommendation A), but introduction of NSAID as 
chemoprevention solely for this purpose requires further research.  
 
Statins 
Statins are usually prescribed as prevention of cardiovascular disease, but may also have a 
cancer preventive effects. Statins have anti-proliferative, pro-apoptotic, anti-invasive, and 
radio-sensitizing properties in pre-clinical studies (60). A meta-analysis (13 studies: 5 cohort 
studies, of which 2 were population-based, 7 case-control studies, of which 6 were 
population-based, and 1 post hoc analysis of 22 RCTs) of individuals without Barrett’s 
esophagus found an adjusted OR of 0.72 for developing esophageal cancer (95% CI 0.60-
0.86), in a sub analysis of patients with Barrett’s esophagus (5 studies: 3 cohort and 2 case-
control studies, of which 1 was population-based) found a 43% reduction in risk of EAC 
(adjusted OR 0.59, 95% CI 0.45-0.78) among users of statins compared to never-users (61). 
However, these results are debated, since a meta-analysis of only randomized clinical trials 
failed to show significant reduction in risk, although this was based on a smaller number of 
esophageal cancer cases (total 164 cancer cases compared to 9285 cancer cases), and no 
separate analysis of only EAC was performed (62). 
Thus, most available studies indicate a preventive effect on the development of EAC of 
treatment with statins (evidence level 3a, grade of recommendation B), but the literature is 
too limited to allow robust conclusions and therefore statins should not be used solely for 
EAC chemoprevention.  
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High-risk individuals for EAC 
To determine who might benefit from preventive measures, high risk individuals for EAC 
need to be identified. A recent Australian prediction model study aiming to identify 
individuals at high risk of developing EAC found that men over 70 years old with a BMI ≥30, 
who were current smokers, experiencing at least weekly symptoms of GERD, were 
medicated with PPIs and had never used NSAIDs were at the highest risk (63). The model 
revealed that the absolute 5-year risk in individuals who fulfilled all of these criteria was 837 
per 100,000 person-years, while the corresponding risks among individuals who were at 
least 60 years old and 50 years old were 506 and 185 per 100,000 person-years, respectively 
(64). A similar study in Sweden identified the highest risk (533 per 100,000 person-years) 
among male smokers, aged 70-74 years, with a BMI ≥25.5, experiencing weekly symptoms 
of GERD for at least five years, and requiring antireflux medication (64). An earlier study on 
the same Swedish study showed that age, sex, BMI and reflux symptoms were the strongest 
predictors of developing EAC, although these factors have not been found to solely explain 
the male predominance (65, 66). Individuals with Barrett’s esophagus have already entered 
the metaplasia-dysplasia-adenocarcinoma-axis. A meta-analysis concluded that the overall 
risk of Barrett’s esophagus to progress to EAC was 6.1/1000 person-years, and twice as high 
among men as women (67), but recently, two large and well-designed studies showed that 
the annual risk of EAC in persons with non-dysplastic Barrett’s esophagus may be lower than 
previously reported, i.e. 0.12% and 0.16% (68, 69). 
Overall, these studies indicate that older men with obesity and GERD are at the highest risk 
of developing EAC, and might benefit most from preventive measures. Individuals with 
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Barrett’s esophagus also constitute a high-risk population, in whom preventive measures 
might be cost-effective. 
 
Conclusions 
This review indicates several promising targets for prevention of EAC among high-risk 
individuals in the clinical setting. The strongest evidence of preventive effects was seen 
following treatment of GERD, particularly after antireflux surgery in individuals with 
Barrett’s esophagus. There is medium level evidence of a preventive effect of tobacco 
smoking cessation in relation to the risk of EAC. There is no substantial evidence showing 
that weight loss, including weight loss after obesity surgery, reduces the risk of EAC, 
although available studies are few in number and have a limited follow-up. Whether 
eradication of H. pylori increases the risk of EAC is unknown, but there is no evidence that 
eradication of H. pylori increases the risk of GERD, which would be believed to mediate any 
increased risk of EAC. HRT might decrease the risk of EAC, but the available studies are few 
in number and more research is required. Use of NSAIDs, both aspirin and non-aspirin, 
seems to prevent EAC, and results from randomized clinical trials are approaching. 
Regarding treatment with statins, the available literature shows a strong risk reduction of 
EAC among patients with Barrett’s esophagus. Yet, more research is needed to establish this 
association. Among these potential options for preventing EAC, clinicians should 
recommend treatment of GERD and tobacco smoking cessation. There is a need for more 
research on these as well as other targets before clinical recommendations can be made, 
and it remains to be established which individuals are most favorable for any such 
preventive actions.  
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Table 1. Associations between the seven preventive targets and risk of esophageal adenocarcinoma (EAC), evidence of preventive effects, and 
the level of evidence according to the Oxford Centre for Evidence-based Medicine.  
Etiological factor Risk of EAC Preventive 
measure 
Best available evidence Prevention of EAC Level of 
evidence
* 
Gastroesophageal 
reflux disease 
Weekly symptoms: OR 4.92, 95% CI 3.90-
6.22 (15) 
Daily symptoms: OR 7.40, 95% CI 4.94-11.1 
(15) 
Medication with 
PPI 
M-A of patients with BE PPI versus no PPI: OR 0.29, 95% CI 0.12-0.79 (20) 3a 
Anti-reflux surgery M-A of patients with BE Antireflux surgery versus medication: IRR 0.46, 95% 
CI 0.20-1.08 (23) 
2a 
Obesity BMI 25-30: RR 1.71, 95% CI 1.50-1.96 (25)  
BMI ≥30: RR 2.34, 95% CI 1.95-2.81 (25)   
BMI ≥40: OR 3.65, 95% CI 2.50-5.34 (26) 
Weight loss by 
obesity surgery 
Not sufficient data   
Tobacco smoking Ever versus never: OR of 2.08, 95% CI 1.83-
2.37 (34) 
Tobacco smoking 
cessation 
Pooled analysis of 10 studies Tobacco smoking cessation <10 years: OR 0.82, 95% 
CI 0.60-1.13 (34) 
Tobacco smoking cessation ≥10 years: OR 0.71, 95% 
CI 0.56-0.89 (34) 
3b 
 
3b 
Helicobacter 
pylori-infection 
Current infection: OR 0.52, 95% CI 0.37-
0.73, (41) and OR: 0.59, 95% CI 0.51-0.68 
(42) 
Helicobacter pylori 
eradication 
M-A of eradication and risk of 
GERD and erosive esophagitis 
Eradication and risk of erosive GERD: OR 1.17, 95 % 
CI 0.94-1.45 (43) 
Eradication and risk of GERD: OR 0.84, 95% CI 0.60-
1.18 (44) 
Eradication and risk of erosive esophagitis: OR 0.97, 
95% CI 0.72-1.31 (44) 
2a 
Hormone 
replacement 
therapy (HRT) 
 Medication with 
HRT 
M-A of women receiving HRT Ever versus never: OR 0.75, 95% CI 0.58-0.98 (50) 3a 
Nonsteroidal anti-
inflammatory 
drugs (NSAID) 
 
 Medication with 
NSAID 
Pooled analysis of 6 studies Daily versus never: OR 0.56, 95% CI 0.43-0.73 (57) 
Occasional versus never: OR 0.66, 95% CI 0.44-1.00 
(57) 
3b 
 
3b 
M-A of 8 RCTs 20 year follow-up Daily versus placebo: HR 0.36, 95% CI 0.21-0.63 (58) 1a 
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Statins  Medication with 
statins 
 
M-A of patients with BE
 
 
M-A of patients irrespective of 
BE
 
Users versus non-users: OR 0.59, 95% CI 0.45-0.78 
(61) 
Users versus non-users: OR 0.72, 95% CI 0.60-0.86 
(61) 
3a 
 
3a 
*Level of Evidence according to the Oxford Centre for Evidence-based Medicine’s levels of evidence; the level of evidence is graded: 1 
(randomized controlled trials), 2 (cohort studies), 3 (case-control studies), 4 (case-series), and 5 (expert opinions); grades 1-3 are also denoted 
as a (systematic review) or b (individual study).(12) 
Abbreviations: EAC, Esophageal adenocarcinoma; OR, Odds ratio; CI, Confidence interval; PPI, Proton-pump inhibitors; M-A, Meta-analysis; BE, 
Barrett’s esophagus; IRR, Incidence risk ratio; BMI, Body mass index; RR, Rate ratio; GERD, Gastroesophageal reflux disease; HRT, Hormone 
replacement therapy; NSAID, Nonsteroidal anti-inflammatory drugs; RCT, Randomized controlled trials; HR, Hazard ratio 
 
